Aseel O. Rataan

Aseel O. Rataan

Auto-generated profile, based on publicly available information

Aseel O. Rataan

Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ARAseel O. Rataan
Aseel O. Rataan
SGSean Geary
Sean Geary
YZYousef Zakharia
Yousef Zakharia
YRYoucef M. Rustum
Youcef M. Rustum
ASAliasger K. Salem
Aliasger K. Salem
Selenium has been extensively evaluated clinically as a chemopreventive agent with variable results depending on the type and dose of selenium used. Selenium species are now being therapeutically evaluated as modulators of drug responses rather than as directly cytotoxic agents. In addition, recent data suggest an association between selenium base-line levels in blood and survival of patients with COVID-19. The major focus of this mini review was to summarize: the pathways of selenium metabolism; the results of selenium-based chemopreventive clinical trials; the potential for using selenium metabolites as therapeutic modulators of drug responses in cancer (clear-cell renal-cell carcinoma (ccRCC) in particular); and selenium usage alone or in combination with vaccines in the treatment of patients with COVID-19. Critical therapeutic targets and the potential role of different selenium species, doses, and schedules are discussed.

Verified
Journal Article
Open access
PDF file
SSSamuel Swearson
Samuel Swearson
ARAseel O. Rataan
Aseel O. Rataan
SESteven Eliason
Steven Eliason
BABrad A. Amendt
Brad A. Amendt
YZYousef Zakharia
Yousef Zakharia
YRYoucef M. Rustum
Youcef M. Rustum
This study was carried out to quantitate the expression levels of microRNA-17, -19a, -34a, -155, and -210 (miRs) expressed in nine clear cell renal cell carcinoma (ccRCC) and one chromophobe renal cell carcinoma cell line with and without sarcomatoid differentiation, and in six primary kidney tumors with matching normal kidney tissues. The data in the five non-sarcomatoid ccRCC cell lines—RC2, CAKI-1, 786-0, RCC4, and RCC4/VHL—and in the four ccRCC with sarcomatoid differentiation—RCJ41T1, RCJ41T2, RCJ41M, and UOK-127—indicated that miR-17 and -19a were expressed at lower levels relative to miR-34a, -155, and -210. Compared with RPTEC normal epithelial cells, miR-34a, miR-155, and miR-210 were expressed at higher levels, independent of the sarcomatoid differentiation status and hypoxia-inducible factors 1α and 2α (HIFs) isoform expression. In the one chromophobe renal cell carcinoma cell line, namely, UOK-276 with sarcomatoid differentiation, and expressing tumor suppressor gene TP53, miR-34a, which is a tumor suppressor gene, was expressed at higher levels than miR-210, -155, -17, and -19a. The pilot results generated in six tumor biopsies with matching normal kidney tissues indicated that while the expression of miR-17 and -19a were similar to the normal tissue expression profile, miR-210, -155, -and 34a were expressed at a higher level. To confirm that differences in the expression levels of the five miRs in the six tumor biopsies were statistically significant, the acquisition of a larger sample size is required. Data previously generated in ccRCC cell lines demonstrating that miR-210, miR-155, and HIFs are druggable targets using a defined dose and schedule of selenium-containing molecules support the concept that simultaneous and concurrent downregulation of miR-210, miR-155, and HIFs, which regulate target genes associated with increased tumor angiogenesis and drug resistance, may offer the potential for the development of a novel mechanism-based strategy for the treatment of patients with advanced ccRCC.

29 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
YZYousef Zakharia
Yousef Zakharia
RRRyan J Reis
Ryan J Reis
MKMatthew R. Kroll
Matthew R. Kroll
ARAseel O. Rataan
Aseel O. Rataan
SMSrija Manchkanti
Srija Manchkanti
YRYoucef Rustum
Youcef Rustum
Purpose: Data on clear-cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of hypoxia-inducible factor-1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC. Patients and Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment). Escalating dose levels of SLM (2,500, 3,000, and 4,000 μg) were administered orally twice daily for 14 days and then once daily concurrently with axitinib 5 mg twice daily using a 3 + 3 design in phase I. Patients were treated at the 4,000 μg dose level in the expansion cohort to obtain preliminary estimates of efficacy. Results: No dose-limiting toxicities occurred at the 4,000 μg SLM dose level. Among the 27 patients treated with 4,000 μg of SLM, the overall response rate was 55.6%, median duration of response was 18.4 months, median progression-free survival was 14.8 months, and median overall survival was 19.6 months. Preliminary results have shown that plasma selenium concentrations, inhibition of TGF-β1, and stabilization of tumor vasculature by SLM are time dependent. Conclusions: SLM (4,000 μg) in sequential combination with axitinib is well tolerated with encouraging efficacy.


1 April 2025
Verified
Other
Open access
YZYousef Zakharia
Yousef Zakharia
RRRyan J Reis
Ryan J Reis
MKMatthew R. Kroll
Matthew R. Kroll
ARAseel O. Rataan
Aseel O. Rataan
SMSrija Manchkanti
Srija Manchkanti
YRYoucef Rustum
Youcef Rustum
Purpose:Data on clear-cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of hypoxia-inducible factor-1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC.Patients and Methods:Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment). Escalating dose levels of SLM (2,500, 3,000, and 4,000 μg) were administered orally twice daily for 14 days and then once daily concurrently with axitinib 5 mg twice daily using a 3 + 3 design in phase I. Patients were treated at the 4,000 μg dose level in the expansion cohort to obtain preliminary estimates of efficacy.Results:No dose-limiting toxicities occurred at the 4,000 μg SLM dose level. Among the 27 patients treated with 4,000 μg of SLM, the overall response rate was 55.6%, median duration of response was 18.4 months, median progression-free survival was 14.8 months, and median overall survival was 19.6 months. Preliminary results have shown that plasma selenium concentrations, inhibition of TGF-β1, and stabilization of tumor vasculature by SLM are time dependent.Conclusions:SLM (4,000 μg) in sequential combination with axitinib is well tolerated with encouraging efficacy.

10 July 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
ARAseel O Rataan
Aseel O Rataan
MAMariam Alameri
Mariam Alameri
GAGhaith M Al-Taani
Ghaith M Al-Taani
HSHadeel K Shreim
Hadeel K Shreim
LALeen H Al-Shalakhti
Leen H Al-Shalakhti
LSLian Shqeer
Lian Shqeer
Objectives: This study aimed to evaluate the knowledge, attitudes and practices (KAP) of Jordanian women regarding post-mastectomy breast reconstruction (PMBR), and to recognise key sociodemographic factors influencing these outcomes. Design: A descriptive cross-sectional study. Setting: Community-based settings across Jordan, representing a general population sample. Participants: A total of 752 adult women were enrolled in the study. Eligible participants were women aged 18 years or older who were living in Jordan. Recruitment took place across a variety of community settings. Data were collected on sociodemographic variables such as age, level of education, insurance coverage and any personal history of breast disease. Primary and secondary outcome measures: The primary outcomes were KAP related to PMBR, measured using a standardised, pretested Arabic questionnaire. Secondary outcomes included identifying sociodemographic factors associated with KAP. Results: Participants demonstrated moderate knowledge (56.2%), a generally positive attitude (48.6%) and moderate practice levels (42.0%) toward PMBR. Regression analysis indicated that age, level of education, insurance status and personal history of breast disease were significant predictors of KAP outcomes. Conclusions: Awareness and use of PMBR among Jordanian women remain inadequate. These results highlight the need for culturally tailored educational initiatives, improved communication between patients and healthcare providers, and the establishment of national guidelines to facilitate informed decision-making. Further studies are warranted to identify barriers to PMBR uptake and to evaluate the impact of targeted awareness interventions.